Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving CVVH
ChiCTR-OPR-16007956Phase 4Recruiting
- Sponsor
- Harbin Medical University
- Start
- Mar 2016
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cefoperazone + sulbactam in Infectious disease (3 arms), sponsored by Harbin Medical University. Started Mar 2016; status: recruiting.
02
Drugs
cefoperazone + sulbactam
03
Conditions
Infectious disease
Beyond the preview
Go deeper on ChiCTR-OPR-16007956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPR-16007956.